Latest Conference Content

Peter A. Lio, MD, clinical assistant professor of dermatology and pediatrics at Northwestern University's Feinberg School of Medicine, describes different methods dermatologists can use to treat atopic dermatitis (AD).

Presenters at American Society of Nephrology Kidney Week 2023 highlighted the importance of understanding the barriers faced by the LGBTQ+ community that impact kidney outcomes and the need to gather better data for studying these issues.

There is great value, both for clinical trials and clinical practice, in biomarkers that identify patients at greatest risk of developing chronic kidney disease (CKD) after acute kidney injury, explained Steven Coca, DO, MS, Icahn School of Medicine at Mount Sinai.

Presenters at the American Society of Nephrology (ASN) Kidney Week 2023 highlighted the exciting new technologies that nephrology research has developed to improve patient outcomes, quality of life, and approaches to care.

Posters at ASN Kidney Week 2023 explored the economic burden brought on by chronic kidney disease (CKD) and further validated the Klinrisk model’s ability to predict progressive forms of CKD.

The use of a bioartificial kidney could save the transplant population from a life of immunosuppression drugs and save costs, according to Shuvo Roy, PhD, professor of bioengineering at the University of California San Francisco.

Mona Shahriari, MD, assistant clinical professor of dermatology at Yale University and associate director of clinical trials at Central Connecticut Dermatology, discusses unique challenges dermatologists face when treating patients with skin of color, who may present differently from White patients.

Presenters at ASN Kidney Week 2023 emphasized the importance of patient education, awareness, and advocacy in the realm of kidney transplantation.

The annual Patient-Centered Oncology Care® (PCOC) meeting returns to Nashville, Tennessee, on November 7-8, bringing oncology stakeholders together for 2 days of discussions and presentations on the rapidly changing oncology care landscape.

Smaller noncoding RNA is being used in clinical practice and as knowledge grows of long noncoding RNA, use of it should follow, explained Laura Denby, PhD, Kidney Research UK Senior Fellow, senior lecturer and principal investigator in the Centre for Cardiovascular Science at the University of Edinburgh.

Two posters presented at Kidney Week 2023 evaluated the global state of chronic kidney disease (CKD) and shed light on delays in CKD diagnoses in the United States.

Presenters at the American Society of Nephrology's Kidney Week 2023 discussed the past, present, and future of pediatric chronic kidney disease, as well as explored the obstacles and solutions for effective trial designs.

Patient-Centered Oncology Care® (PCOC) 2023 has a diverse group of people coming in to discuss oncology, including payment reform and the future of oncology care, said Lalan Wilfong, MD, The US Oncology Network.

Afreen Shariff, MD, MBBS, Duke Cancer Institute, discusses the challenges and benefits of electronic consults (e-consults) for patients with cancer currently undergoing treatment who have a comorbidity history or who develop an endocrine system disorder because of treatment.

The addition of durvalumab to first-line chemotherapy, followed by maintenance treatment with durvalumab plus olaparib significantly improved progression-free survival in patients with newly diagnosed advanced or recurrent endometrial cancer, according to data from the phase 3 DUO-E/GOG-3041/ENGOT-EN10 trial.

The American Society of Nephrology (ASN) Kidney Week 2023 will take place in Philadelphia, Pennsylvania, from November 2-5, as experts from across the globe gather to discuss the latest innovations in renal care and current issues facing the field.

Saira Jan, PharmD, MS, of Horizon Blue Cross Blue Shield of New Jersey, discussed cost savings that occurred so far from their collaborative pilot program with Rutgers Cancer Institute of New Jersey and RWJ Barnabas Health and also noted those they predict to occur as the program continues.

April Armstrong, MD, MPH, of University of California, Los Angeles, discussed how recent biologics advancements improved moderate-to-severe atopic dermatitis (AD) treatment.

Saira Jan, PharmD, MS, of Horizon Blue Cross Blue Shield of New Jersey, provides an overview of their collaborative pilot program with Rutgers Cancer Institute of New Jersey and RWJ Barnabas Health, discussing the program's origin, objectives, and beyond.

The phase 4 ANNEXA-I trial was stopped early after showing superior hemostatic efficacy and the capability to limit potentially life-threatening intracerebral hemorrhage (ICH) compared with usual care in patients taking oral factor Xa (FXa) inhibitors.

Mona Shahriari, MD, assistant clinical professor of dermatology at Yale University and associate director of clinical trials at Central Connecticut Dermatology, provides on overview of the treatment landscape in patients with skin of color with plaque psoriasis.

Through the integration of a population health reimbursement model in 2020, Allina Health Cancer Institute was able to implement expanded screening initiatives through the use of artificial intelligence and precision medicine, according to Mike Koroscik, MBA, MHA, vice president of oncology, Allina Health.

April Armstrong, MD, MPH, of University of California, Los Angeles, gave an overview of her Fall Clinical Dermatology session on treating atopic dermatitis (AD) in patients with diverse skin tones and weighed in on how to address related treatment barriers.

A poster presented at AMCP Nexus 2023 reported that payers believe implementing the Inflation Reduction Act (IRA) will impact Medicare Part D plans financially.

Landon Marshall, PharmD, PhD, of Prime Therapeutics, discusses the benefits of gene therapy forecasting for health insurers and what future advancements can be expected.

MARIPOSA demonstrated the combination reduced risk of progression or death by 30% compared with osimertinib. MARIPOSA-2 found amivantamab plus chemotherapy and amivantamab plus chemotherapy and lazertinib also improved progression-free survival (PFS) over chemotherapy after progression on osimertinib.

Timothy O'Shea, PharmD, MS, discussed the most surprising findings from a home infusion pilot program and explained how he thinks home infusion will continue to evolve.

Helen Shih, MD, MS, MPH, FASTRO, Massachusetts General Hospital, weighs the risks and benefits of treating or postponing treatment of low-grade gliomas.